RESEARCH AND DEVELOPMENT AGREEMENT among ITI SCOTLAND LIMITED and INVERNESS MEDICAL INNOVATIONS, INC. and STIRLING MEDICAL INNOVATIONS LIMITED and INVERNESS MEDICAL SWITZERLAND, GMBH 25 February 2005Research and Development Agreement • May 10th, 2005 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • Delaware
ITI SCOTLAND LIMITED, incorporated in Scotland under the Companies Acts with registered number SC251900 and having its registered office at 180 St. Vincent Street, Glasgow, G2 5SG (“ITI”); and
FOURTH SUPPLEMENTAL INDENTUREFourth Supplemental Indenture • May 10th, 2005 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • New York
THIS FOURTH SUPPLEMENTAL INDENTURE, dated as of March 31, 2005 (this “Fourth Supplemental Indenture”), to the Indenture (as defined below), among Inverness Medical Innovations, Inc., a Delaware corporation (the “Issuer”), the Guarantors (as defined in the Indenture), Binax, Inc., a Delaware corporation (the “Additional Guarantor”) and U.S. Bank Trust National Association, as Trustee (the “Trustee”).
THIRD SUPPLEMENTAL INDENTUREThird Supplemental Indenture • May 10th, 2005 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • New York
THIS THIRD SUPPLEMENTAL INDENTURE, dated as of March 16, 2005 (this “Third Supplemental Indenture”), to the Indenture (as defined below), among Inverness Medical Innovations, Inc., a Delaware corporation (the “Issuer”), the Guarantors (as defined in the Indenture), Ischemia Technologies, Inc., a Delaware corporation (the “Additional Guarantor”) and U.S. Bank Trust National Association, as Trustee (the “Trustee”).
TWELFTH AMENDMENT AND CONSENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENTCredit Agreement • May 10th, 2005 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • New York
THIS TWELFTH AMENDMENT AND CONSENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT, dated as of March 15, 2005 (this “Amendment”), to the Second Amended and Restated Credit Agreement, dated as of September 30, 2003 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among General Electric Capital Corporation, as Agent and Lender (“Agent”), Inverness Medical Innovations, Inc. (“Innovations”), Wampole Laboratories, Inc. and Inverness Medical (UK) Holdings Limited, as borrowers (“Borrowers”), the other Credit Parties signatory thereto, Merrill Lynch Capital, a division of Merrill Lynch Business Financial Services Inc., as documentation agent, co-syndication agent and lender, UBS Securities LLC, as co-syndication agent, and the lenders signatory thereto from time to time (collectively, the “Lenders”).
